BCR and chronic myelogenous leukemia, BCR-ABL1 positive: As the tyrosine kinase activity of BCR-ABL is essential for its transforming ability [11], specific targeting of the BCR-ABL tyrosine kinase provides a promising strategy for CML therapy.